Where Pacira BioSciences Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analysts have mixed ratings for Pacira BioSciences (NASDAQ:PCRX), with a recent decline in the average 12-month price target by 25.15%. The company has shown solid financial performance with notable revenue growth, net margin, ROE, and ROA, but analysts have lowered their price targets and ratings in response to market conditions.
August 12, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pacira BioSciences (NASDAQ:PCRX) has received mixed ratings from analysts, with a notable 25.15% decline in the average 12-month price target. Despite solid financial performance, including a 5.05% revenue growth rate and strong net margins, analysts have lowered their price targets and ratings due to market conditions.
The decline in the average 12-month price target by 25.15% and the lowering of ratings by multiple analysts indicate a bearish short-term outlook for PCRX. Despite strong financial metrics, the market conditions and analysts' adjustments suggest potential downward pressure on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100